Drug Trial Radar · NCT07164170
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Dec 30, 2028
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
Conditions
- Non-Small Cell Lung Cancer
Interventions
ABSK043 in combination with GlecirasibDrug
Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose. Based on the accumulated safety data and PK profile, the Safety Review Committee (SRC), composed of the investigator and the sponsor, may discuss and agree to allow exploration of other possible doses. Dose confirmation cohort (Part B) and Expansion cohort Patients in dose confirmation cohort and expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity. All patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 21 days)
- AEsTime frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of Glecirasib, whichever occurs first, up to 30 months.
- SAEsTime frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of Glecirasib, whichever occurs first, up to 30 months.
- AESIs AESIsTime frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of Glecirasib, whichever occurs first, up to 30 months.
- ORRTime frame: From date of enrolment#Cycle1 Day1# until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator's decision to discontinue treatment, or end of study, whichever comes first, assessed up to 50 months.
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institude
Nanning, Guangxi, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Tongji Hospital Tongji Medical College of Hust
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospitial
Changsha, Hunan, China · Recruiting
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Central Hospital Affiliated to Shangdong First Medical University
Jinan, Shangdong, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Not yet recruiting
West China Hospital Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.